tyrosine kinase inhibitors

News
TKI Discontinuation Associated With Improved PROs in CML
12/03/2020
12/03/2020
Journal of Clinical Pathways
Trend in TKI Use, Adherence, and Switching Patterns in Patients With CML: Before and After the Availability of Generic Imatinib
Research Reports
Trend in TKI Use, Adherence, and Switching Patterns in Patients With CML: Before and After the Availability of Generic Imatinib
08/19/2020
Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...
Abstract: The therapeutic landscape for chronic myeloid leukemia (CML) has evolved substantially over the past decade, most notably with the introduction of second- and third-generation tyrosine kinase inhibitors...
...
08/19/2020
Journal of Clinical Pathways
Research in Review
Novel Therapy Plus Gemcitabine Does Not Improve OS in Pancreatic Cancer
04/11/2017
JCP Editors
A new tyrosine kinase inhibitor (TKI) in combination with gemcitabine does not improve overall survival (OS) any more than gemcitabine alone for patients with advanced pancreatic cancer, according to research...
A new tyrosine kinase inhibitor (TKI) in combination with gemcitabine does not improve overall survival (OS) any more than gemcitabine alone for patients with advanced pancreatic cancer, according to research...
A new...
04/11/2017
Journal of Clinical Pathways
Research in Review
Novel TKI Therapy Plus Gemcitabine Does Not Improve OS in Pancreatic Cancer
03/09/2017
JCP Editors
A new tyrosine kinase inhibitor (TKI) in combination with gemcitabine does not improve overall survival (OS) any more than gemcitabine alone for patients with advanced pancreatic cancer, according to a study...
A new tyrosine kinase inhibitor (TKI) in combination with gemcitabine does not improve overall survival (OS) any more than gemcitabine alone for patients with advanced pancreatic cancer, according to a study...
A new...
03/09/2017
Journal of Clinical Pathways
Research in Review
TKI Discontinuation Improves Remission Rates for Patients With CML
03/03/2017
JCP Editors
Patients with chronic myeloid leukemia (CML) who discontinued treatment with second-generation tyrosine kinase inhibitors (TKIs) benefited from significant treatment-free remission rates, according to research...
Patients with chronic myeloid leukemia (CML) who discontinued treatment with second-generation tyrosine kinase inhibitors (TKIs) benefited from significant treatment-free remission rates, according to research...
...
03/03/2017
Journal of Clinical Pathways
Research in Review
Most Cost-Effective Sequence of TKIs for Treatment of GISTs Identified
01/10/2017
JCP Editors
The best potential strategy involving tyrosine kinase inhibitors (TKIs) for the treatment of gastrointestinal stromal tumors (GISTs) has been identified, according to new research published in Clinical Drug...
The best potential strategy involving tyrosine kinase inhibitors (TKIs) for the treatment of gastrointestinal stromal tumors (GISTs) has been identified, according to new research published in Clinical Drug...
The...
01/10/2017
Journal of Clinical Pathways
Research in Review
Varying Toxicities Between EGFR-TKIs for Treatment of NSCLC
12/29/2016
JCP Editors
Varying degrees of toxicity risks between different epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) can help inform treatment decisions for individual patients with non-small cell lung...
Varying degrees of toxicity risks between different epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) can help inform treatment decisions for individual patients with non-small cell lung...
...
12/29/2016
Journal of Clinical Pathways
Research Reports
Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations
05/06/2016
Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...
Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...
...
05/06/2016
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use